ENDOPORE
LIVE

Serial Number

79379326

Owner

VITARKA THERAPEUTICS LTD

Attorney

Jordan Arnot Leahey

Filing Date

Jul 25, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ENDOPORE Trademark

Serial Number: 79379326 • Registration: 7805555

ENDOPORE is a trademark filed by VITARKA THERAPEUTICS LTD on July 25, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

VITARKA THERAPEUTICS LTD

Innovation House Innovation Way,

Entity Type: 99

Trademark Details

Filing Date

July 25, 2023

Registration Date

May 27, 2025

Published for Opposition

April 8, 2025

Goods & Services

Compilation of information into computer databases in the medical field

Pharmaceutical preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of drugs for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of therapeutic substances for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of proteins for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of peptides for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of small molecules for the treatment of cancer, tumours, neuropathic pain, neurological diseases and neurodegenerative diseases; pharmaceutical compositions and preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer

Scientific and technological services, namely, scientific research, technological research, and research and design, all in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; research services in the fields of intracellular delivery of drugs, gene editing, intracellular delivery of therapeutic substances focused on the development of RNA therapies, intracellular delivery of therapeutic substances focused on non-viral delivery technology, intracellular delivery of nucleic acids, intracellular delivery of proteins, intracellular delivery of peptides, and intracellular delivery of small molecules; clinical trials, namely, scientific research in the nature of conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; medical research, namely, services for assessing the efficacy of pharmaceuticals; information, advisory and consultancy services relating to all of the aforesaid

Medical services; medical analysis for the diagnosis and treatment of persons; pharmacy advice, namely, preparation of prescriptions in pharmacies and providing medical advice related to pharmaceutics; advisory services relating to health; advisory services relating to medical services; health care, namely, arranging of medical treatment; consultancy relating to health care; health advice and information services; health care; health care services; health centres being health clinic services; health clinic services; information services relating to health care; medical information retrieval services; health care, namely, medical treatment services; medical health assessment services; health care, namely, preparation of reports relating to health care matters; professional consultancy relating to health; providing health information; provision of health care services; provision of medical services; provision of medical information relating to medical practitioners; provision of medical information relating to medical specialists; services for the provision of medical care information; information, advisory and consultancy services relating to all of the aforesaid

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 8, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 21, 2025 FICS
FINAL DISPOSITION PROCESSED
Dec 21, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 27, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 27, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
May 27, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 8, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 8, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 2, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 14, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 14, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 14, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 14, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 14, 2025 CNEA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 8, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 20, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 20, 2025 OPNR
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jan 15, 2025 LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Nov 14, 2024 LIMN
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 14, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 14, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 14, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 10, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 10, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 10, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 10, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 10, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 10, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 10, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 10, 2024 COAR
LIMITATION OF GOODS RECEIVED FROM IB
Aug 2, 2024 LIMG
LIMITATION OF GOODS RECEIVED FROM IB
Jul 19, 2024 LIMG
REFUSAL PROCESSED BY IB
May 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 17, 2024 RFCS
REFUSAL PROCESSED BY MPU
Apr 17, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 31, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 30, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 27, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 26, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 22, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 21, 2023 REPR